59514 Shares in BioXcel Therapeutics, Inc. Purchased by Virtu Financial LLC - Defense World
BTAI Stock | USD 0.43 0.01 2.27% |
Under 66% of BioXcel Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding BioXcel Therapeutics suggests that many traders are alarmed. BioXcel Therapeutics' investing sentiment shows overall attitude of investors towards BioXcel Therapeutics.
BioXcel |
59514 Shares in BioXcel Therapeutics, Inc. Purchased by Virtu Financial LLC Defense World
Read at news.google.com
BioXcel Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards BioXcel Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BioXcel Therapeutics Fundamental Analysis
We analyze BioXcel Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioXcel Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioXcel Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
BioXcel Therapeutics is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
BioXcel Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioXcel Therapeutics stock to make a market-neutral strategy. Peer analysis of BioXcel Therapeutics could also be used in its relative valuation, which is a method of valuing BioXcel Therapeutics by comparing valuation metrics with similar companies.
Peers
BioXcel Therapeutics Related Equities
XFOR | X4 Pharmaceuticals | 13.43 | ||||
VKTX | Viking Therapeutics | 2.84 | ||||
EXEL | Exelixis | 0.54 | ||||
ABOS | Acumen Pharmaceuticals | 0.46 | ||||
TGTX | TG Therapeutics | 0.06 | ||||
MREO | Mereo BioPharma | 0.26 | ||||
DAWN | Day One | 0.45 | ||||
INZY | Inozyme Pharma | 0.67 | ||||
APLS | Apellis Pharmaceuticals | 1.85 | ||||
MDGL | Madrigal Pharmaceuticals | 1.99 | ||||
AMLX | Amylyx Pharmaceuticals | 3.10 | ||||
TERN | Terns Pharmaceuticals | 3.18 | ||||
ELEV | Elevation Oncology | 4.00 | ||||
HEPA | Hepion Pharmaceuticals | 6.35 |
Complementary Tools for BioXcel Stock analysis
When running BioXcel Therapeutics' price analysis, check to measure BioXcel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioXcel Therapeutics is operating at the current time. Most of BioXcel Therapeutics' value examination focuses on studying past and present price action to predict the probability of BioXcel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioXcel Therapeutics' price. Additionally, you may evaluate how the addition of BioXcel Therapeutics to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |